These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19467157)

  • 21. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials.
    Shi Y; Wu YH; Shu ZY; Zhang WJ; Yang J; Chen Z
    Hepatobiliary Pancreat Dis Int; 2010 Oct; 9(5):462-72. PubMed ID: 20943454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
    van Zonneveld M; Zondervan PE; Cakaloglu Y; Simon C; Akarca US; So TM; Flink HJ; de Man RA; Schalm SW; Janssen HL;
    Liver Int; 2006 May; 26(4):399-405. PubMed ID: 16629642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
    Liaw YF
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S73-5. PubMed ID: 15546254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.
    Chan HL; Hui AY; Wong VW; Chim AM; Wong ML; Sung JJ
    Hepatology; 2005 Jun; 41(6):1357-64. PubMed ID: 15880608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymosin in the treatment of HBeAg-negative chronic hepatitis B.
    Saruc M; Ozden N; Yuceyar H
    Med Sci Monit; 2003 Aug; 9(8):RA198-202. PubMed ID: 12942046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis.
    Kim V; Abreu RM; Nakagawa DM; Baldassare RM; Carrilho FJ; Ono SK
    J Viral Hepat; 2016 Mar; 23(3):154-69. PubMed ID: 25967226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
    Chan HL; Leung NW; Hui AY; Wong VW; Liew CT; Chim AM; Chan FK; Hung LC; Lee YT; Tam JS; Lam CW; Sung JJ
    Ann Intern Med; 2005 Feb; 142(4):240-50. PubMed ID: 15710957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation on HBeAg conversion time when treating chronic hepatitis B patients with combination of lamivudine and traditional Chinese medicine].
    Bai SL; Hu XY; Zhong S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Dec; 29(12):1243-7. PubMed ID: 19173973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
    Zhu SS; Dong Y; Zhang HF; Wang LM; Xu ZQ; Zhang M; Gan Y; Chen DW; Wang FC; Yan JG; Zhao P
    Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):604-609. PubMed ID: 31594077
    [No Abstract]   [Full Text] [Related]  

  • 34. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.
    Yoon SK; Jang JW; Kim CW; Bae SH; Choi JY; Choi SW; Lee YS; Lee CD; Chung KW; Sun HS; Kim BS
    Intervirology; 2005; 48(6):341-9. PubMed ID: 16024938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical trial of sequential antiviral therapy for patients with chronic hepatitis B in China].
    Lei CL; Peng XM; Tang XP; Yang Z; Fan HM; Yuan XZ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Mar; 18(1):69-72. PubMed ID: 15340532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.
    Schalm SW; Heathcote J; Cianciara J; Farrell G; Sherman M; Willems B; Dhillon A; Moorat A; Barber J; Gray DF
    Gut; 2000 Apr; 46(4):562-8. PubMed ID: 10716688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.
    Lau GK; Nanji A; Hou J; Fong DY; Au WS; Yuen ST; Lin M; Kung HF; Lam SK
    J Viral Hepat; 2002 Jul; 9(4):280-7. PubMed ID: 12081605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials.
    Rudin D; Shah SM; Kiss A; Wetz RV; Sottile VM
    Liver Int; 2007 Nov; 27(9):1185-93. PubMed ID: 17919229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in [corrected] patients with chronic hepatitis B lacking HBeAg in China [corrected].
    You J; Zhuang L; Cheng HY; Yan SM; Qiao YW; Huang JH; Tang BZ; Ma YL; Wu GB; Qu JY; Wu RX
    J Chin Med Assoc; 2005 Feb; 68(2):65-72. PubMed ID: 15759817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.